WO2008036021A1 - Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands - Google Patents

Abstract

The present invention provides tetrahydro-lH-pyrido [3, 4- b] indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds act as cannabinoid receptor ligands (CB1) and thus may be used in the treatment of pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.

Description

Tetrahydro- lH-pyrido [3 , 4 -b] indole derivatives as CBl receptor ligands

BACKGROUND OF THE INVENTION

5 1. Field of the invention

The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's0 chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.

2. Discussion of Relevant Technology

Pain management has been studied for many years. It is known that 5 cannabinoid receptor (e.g., CBi receptor, CB₂ receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CBi and/or CB₂ receptors. Generally, CBi receptors are located predominately in the central nervous system, whereas CB₂ receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived0 from the immune system.

While CBi receptor agonists, such as Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be5 mediated by the CBi receptors located in CNS. There are lines of evidence, however, suggesting that CBi agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile. Therefore, there is a need for new CBi receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with0 reduced or minimal undesirable CNS side-effects.

DESCRIPTION OF THE EMBODIMENTS The present invention provides CBi receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.

The term "C_m._n" or "C_m-π group" refers to any group having m to n carbon atoms. The term "alkyl" refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms. Illustrative examples of alkyls include, but are not limited to, Cμδalkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2 -propyl, 2-methyl-l -butyl, 3-methyl-l-butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-methyl-l-pentyl, 4- methyl- 1 -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2- dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl can be unsubstituted or substituted with one or two suitable substituents. The term "cycloalkyl" refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. Examples of cycloalkyls include, but are not limited to, Cs^cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl is a monocyclic ring or bicyclic ring. The term "cycloalkenyl" refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.

The term "aryl" refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g. , 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms.

The term "heterocycle" refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the riαg(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

The term "heteroaromatic" refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (e.g., 4n + 2 delocalized electrons).

The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

The term "heterocyclyl" refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.

The term "heterocyclylene" refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

The term "heteroaryl" refers to a heterocyclyl having aromatic character.

The term "heterocylcoalkyl" refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as C3.6heterocycloalkyl.

The term "six-membered" refers to a group having a ring that contains six ring atoms.

The term "five-membered" refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl. A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro- pyridinyl, piperazinyl, moφholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3- dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-lH-azepinyl, homopiperazinyl, 1,3- dioxepanyl, 4,7-dihydro-l,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3- triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4- thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indoliαyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4- benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3- dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl. In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" refers to radicals of the general formula -O-R, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.

Halogen includes fluorine, chlorine, bromine and iodine.

"RT" or "rt" means room temperature.

In one aspect, an embodiment of the invention provides a compound of Formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

wherein

selected from piperidine, pyrrolidine, azetidine, and azepane ;

R¹ is selected from Ci-βalkyl and C3_₆cycloalkyl;

R² is selected from -H, Ci_-6alkyl, C_2-6alkenyl, -C(=O)-NR⁹R¹⁰, -S(=O)₂- NR⁹R¹⁰, -S(=O)₂-C_1-6alkyl, -S(=O)₂-C_6-10aryl, -S(=O)₂-C₃.₅heteroaryl, -C(=O)- Cμ_δalkyl; Cg-ioaryl-Ci^alkyl; and Cs-sheteroaryl-Ci^alkyl, wherein said Ci.βalkyl, C_2-6alkenyl, -S(=O)₂-Ci_-6alkyl, -S(=0)₂-C_6-ioaryl, -S(=O)₂-C_3-5heteroaryl, -C(O)- Ci.βalkyl; C_δ-ioaryl-Ci^alkyl; and C_3-5heteroaryl-Ci.₄alkyl used in defining R² is optionally substituted with one or more group selected from -OR, R, -CO₂H, -CO₂-R; -SO₂-R; halogen, -NO₂, -OH, -NH₂, -NHR, -C(=O)-NH₂, and -C(=O)-NHR; R³ is selected from Q-eheterocycloalkyl, C3.6heterocycloalkyl-Ci_-4alkyl, C₃-₆cycloalkyl, C3-₆cycloalkyl-Ci.₄alkyl, Q-ealkyl, C_2-6alkenyl,

C_{3- 6}heteroaryl-Ci_-4alkyl, -C(=O)-Ci_-6alkyl, -C(=O)-C_3-6cycloalkyl and -C(=NH)-Ci. βalkyl, wherein said Cs-βheterocycloalkyl, Ca-βheterocycloalkyl-Ci^alkyl, C₃-₆cycloalkyl,

C_halky! C₂-₆alkenyl,

C_{3- 6}heteroaryl-Ci.₄alkyl, -C(=O)-C_3-6cycloalkyl and -C(=NH)-Ci. βalkyl used in defining R³ is optionally substituted with one or more groups selected from -OR, R, NO₂, -CO₂H₅ -CO₂-R; -SO₂-R; halogen; -OH; -NH₂; -NHR, -C(=0)- NH₂, and -C(=O)-NHR; R is Ci_-6alkyl; and

R⁹ and R¹⁰ are independently selected from — H, C^aHcyl, Cg^oaryl, Cβ-ioaryl- Ci_₄alkyl, Cs^heterocyclyl, Cs-βheterocyclyl-C_Malkyl, C_2-6alkenyl, C₃-₆cycloalkyl, and

hydroxy-Ci-βalkyl and Ci-galkoxy-Ci-βalkyl. In another embodiment, R¹ is selected from methyl, ethyl and cyclopropyl.

In a further embodiment, R² is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, t-butyl, allyl, -S(=O)₂-CH₃, -S(=O)₂-CH₂CH₃, 2-methoxyethyl, tetrahydropyran-4-yl-methyl, 1-propylsulfonyl, methylsulfonyl, ethylsulfonyl, cyclopropylsulfonyl, phenyl, phenylsulfonyl, 2-(methoxycarbonyl)-phenylsulfonyl; 2- (hydroxycarbonyl)-phenylsulfonyl, l-methyl-lH-imidazol-4-yl-sulfonyl, IH- imidazol-1-yl-sulfonyl, furylsulfonyl, (5-methylisoxazol-4-yl)sulfonyl, morpholin-4- ylcarbonyl, 4-amino-phenyl, -CH₂-C(=O)-N(CH₃)₂, -C(=O)-N(CH₃)₂, -S(=0)₂- N(CH₃)₂, -SC=O)₂-NHCH₂CH₃, -C(=O)-CH₂CH₂CH₃, -CH₂-C(=O)-OCH₃, -CH₂- C(=O)-OCH₂CH₃, -CH₂-CO₂H, benzyl, 4-aminobenzyl, 4-nitrobenzyl, 4- methylsulfonyl-benzyl, 4-methylthio-benzyl, 4-acetylamino-benzyl, 4-methoxy- benzyl, 4-ethoxy-benzyl, 2,6-difluorobenzyl, (6-chloro-l,3-benzodioxol-5-yl)methyl, (5-ethoxycarbonyl)-fur-2-yl-methyl, (2-methyl-l,3-thiazol-4-yl)-methyl, (5-methyl- isoxazol-4-yl)-methyI, pyridin-2-yhnethyl, cyclobutylmethyl, and cyclopropyknethyl. In another embodiment, R³ is selected from ethyl, isopropyl, propyl, 2-methy- propyl, 1-butyl, 1-pentyl, l-acetyI-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutyhnethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 2-pyrimidinyl, 1- iminoethyl, 2-pyridinyl, 3,4,5,6-tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, 2- pyridinyl-methyl, 3-pyridinylmethyl, 4-pyridinylmethyl, l-methyl-4-piperidinyl, 4- piperidinyl, (6-methyl-pyridin-2-yl)metiiyl, (2-ethyl-4-methyl-lH-imidazol-5- yl)methyl, tetrahydrofuran-2-yl, tetrahydroftιxan-3-yl, tetrahydroftiran-3-ylmethyl, 1- ethyl- 1 H-pyrazol-4-yl, 1 ,3 -dimethyl- 1 H-pyrazol-5-yl, (3 -methylpyridin-4-yl)methyl, l,3-oxazol-2-ylmethyl, l,3-oxazol-5-ylmethyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H-pyran-4-ylmethyl, 2-phenylethyl, 2-methoxyben2yl, 3,3,3- trifluoropropyl, 2,2-difluoroethyl, 2-hydroxycyclopentyl, (l-ethyl-3-methyl-lH- pyrazol-5-yl)methyl, 2,l,3-benzoxadiazol-5-ylmethyl, 3-thienylmethyl, 2- trifmoromethyl-benzyl, 3-methylbutyl, cyclohex-3-en-l-ylmethyl, 2-fluoro-6- methoxybenzyl, 2-phenyl-propyl, 2-ethyl-butyl, cyclobutylcarbonyl, 2,2- difluoropropanoyl, cyclopentylcarbonyl, tetrahydro-2H-pyran-4-ylcarbonyl, cyclopropylcarbonyl, propylcarbonyl, N-ethylaminocarbonyl, N- isopropylaminocarbonyl, cyclopropylsulfonyl, and ethylsulfonyl.

In a further embodiment, R³ is selected from ethyl, isopropyl, propyl, 2- methy-propyl, 1 -butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentyhnethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 1-iminoethyl, 3,4,5,6-tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, tetrahydrofuran-3- ylmethyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, l-methyl-4-piperidiαyl, 2- (tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H-pyran-4-ylmethyl, 3,3,3- trifluoropropyl, 2,2-difluoroethyl, 2-hydroxycyclopentyl, 3-methylbutyl, cyclohex-3- en-1-ylmethyl, and 2-ethyl-butyl.

In an even further embodiment, R³ is selected from cyclopentyl and 4- tetrahydro-2H-pyranyl. It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter. It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the Formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I. Within the scope of the invention are also salts of the compounds of the

Formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

In one embodiment, the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or /j-toluenesulphonate.

We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CBi receptors. More particularly, the compounds of the invention exhibit selective activity as agonist of the CBi receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CBi receptors is present or implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, obesity, gastrointestinal disorders and cardiovascular disorders. Even furthermore, the compounds of the invention may be useful in enhancing smoking cessation.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, obesity, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids. Also within the scope of the invention is the use of any of the compounds according to the Formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy. In a further aspect, the present invention provides the use of a compound of

Formula I or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in tiierapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be contrued accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, transdermally, intracerebroventricularly and by injection into the joints. In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify.

Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition. A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

Within the scope of the invention is the use of any compound of Formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of Formula I for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such therapy.

Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain. Further, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

Biological Evaluation hCBj and hCB^ receptor binding

Human CBi receptor from Receptor Biology (hCBi) or human CB2 receptor from BioSignal (hCB₂) membranes are thawed at 37 ⁰C, passed 3 times through a 25- gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl₂, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC₅₀ of the compounds of the invention at hCBi and I1CB₂ are evaluated from 10-point dose-response curves done with ³H-CP55,940 at 20000 to 25000 dpm per well (0.17- 0.21 nM) in a final volume of 300 μl. The total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl₂, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 ⁰C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid.

hCBj and hCB? GTPγS binding

Human CBi receptor from Receptor Biology (hCBi) or human CB₂ receptor membranes (BioSignal) are thawed at 37 ⁰C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTPγS binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, 0.1% BSA). The EC₅₀ and E_max of the compounds of the invention are evaluated from 10-point dose- response curves done in 300μl with the appropriate amount of membrane protein and 100000-130000 dpm OfGTPg³⁵S per well (0.11 -0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μM (hCB₂) or 10 μM (hCBi) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μM (hCB2) or 112.5 μM (hCBj) GDP prior to distribution in plates (15 μM (hCB₂) or 30 μM QxCBi) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl₂, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 ⁰C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist. Based on the above assays, the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation:

Ki = IC_S0/(l+[rad]/Kd),

Wherein IC50 is the concentration of the compound of the invention at which 50% displacement has been observed;

[rad] is a standard or reference radioactive ligand concentration at that moment; and

Kd is the dissociation constant of the radioactive ligand towards the particular receptor. Using the above-mentioned assays, the compounds of the invention are found to be active towards human CBi receptors.

EXAMPLES

The invention will further be described in more detail by the following

Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

Example 1 iV-Cyclopropyl-l-{[5-methyI-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro- Lff-pyrido [4,3-δ]indol-8-yl] carbonyl}piperidine-3-carboxamide

Step A: iV-Cyclopropyl-l-{[5-methyI-2-(tetrahydro-2iϊ-pyran-4-yl)-2,3,4,5- tetrahydro-LET-pyrido^_jS-Alindol-S-yycarbonylJpiperidine-S-carboxamide

5-Methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-δ]indole-8- carboxylic acid (30 mg, 0.1 mmol) (see following steps B, C, D, E, F, G, and Η for its preparation) and N-cyclopropylpiperidine-4-carboxamide (TFA salt) (56 mg, 0.2 mmol) (see following steps I and J for its preparation) were dissolved in dry DMF (5 mL), followed by addition of N,N-diisopropylethylamine(70 uL, 0.4 mmol) . After the mixture was cooled down to 0 ⁰C, ΗATU (46 mg, 0.12 mmol) was added in portion and the reaction was stirred overnight at room temperature. The reaction mixture was concentrated, extracted with EtOAc, washed with water and brine. The crude product was purified by Gilson using low pΗ column 10-30% acetonitrile gradient to give the title compound as a white solid (TFA salt, 20 mg, 34%). ¹H ΝMR (400 MHz, METHAΝOL-D4) δl.27 - 1.40 (m, 6 H) 1.87 - 1.99 (m, 4 H) 3.17 - 3.29 (m, 6 H) 3.44 - 3.56 (m, 5 H) 3.66 - 3.74 (m, 6 H) 3.75 (s, 3 H) 4.13 (dd, J=11.43, 4.59 Hz, 2 H) 7.27 (d, J=8.59 Hz, 1 H) 7.49 (d, /=8.59 Hz, 1 H) 7.60 (s, 1 H); MS (APPI) (M+H)⁺= 465.3

Step B. 2,3,4,5-Tetrahydro-lH-pyrido[4-3b]indole-8-carboxylic acid

In a 3L round bottom flask with a mechanical stirrer, 3-hydrazinoic acid hydrochloride (55.3 g, 0.29 mol) and 4-piperidone hydrochloride monohydrate (45 g, 0.29 mol) were heated at reflux with dioxane (IL) and hydrochloric acid 12N (100 mL) for 17 hours. After cooling at room temperature, the dioxane was removed by evaporation and ethanol (100 mL) was added. The suspension was cooled in an ice bath and the solid was collected by filtration and washed with ethanol to give 87.7 g (118%) of crude product, which contained ammonium chloride as the impurity and was used in the next step without further purification. ¹H-NMR (300 MHz, DMSO-ck) δ 12.44 (s, IH), 11.63 (s, IH), 8.13 (s, IH), 7.70 (dd, IH, J= 1.6, 8.5 Hz), 7.38 (d, IH, J= 9.2 Hz), 4.32 (s, 2H), 3.45-3.38 (m, 2H), 3.03 (t, 2H, J= 5.7 Hz).

Step C. 2,3,4,5-Tetrahydro-l#-pyrido[4-3b]indoIe-8-methyl carboxylate

The carboxylic acid (87.7 g) was mixed with methanol in a 3L round bottom flask and cooled in an ice bath. Acetyl chloride (100 mL) was slowly added and the ice bath was removed. The mixture was heated at reflux for 3.5 hours. After cooling at room temperature, the mixture was concentrated by evaporation of methanol and the solid was collected by filtration as the desired product (87.3 g, 111 % for two steps) that was still containing ammonium chloride. ¹H-NMR (300 MHz, DMSO-J₆) δ 11.69 (s, IH), 9.66 (s, IH), 8.16 (s, IH), 7.71 (dd, IH, /= 1.6, 8.6 Hz), 7.41 (dd, IH, J= 0.5, 8.5 Hz), 4.33 (s, 2H), 3.82 (s, 3H), 3.43 (s, 2H), 3.03 (t, 2H, J= 5.9 Hz).

Step D. 2-Boc-2,3,4,5-tetrahydro-lH-pyrido[4-3b]indole-8-methyl carboxylate

The crude amine (87.3 g) was stirred in methanol (1,5 L) in an ice bath. Then 5N sodium hydroxide solution (60 mL) was slowly added, followed by addition of Boc anhydride (80 g 0.366 mol). The mixture was stirred at room temperature for 2.5 hours. The starting material then disappeared by TLC (AcOEt). The mixture was concentrated by evaporation of methanol and the solid was collected by filtration to give a pink solid (97.3 g, quantitative yield for 3 steps). ¹H-NMR (300 MHz, DMSO- d₆) δ 11.39 (s, IH), 8.06 (s, IH), 7.67 (dd, IH, J= 1.7, 8.5 Hz), 7.36 (d, IH, J= 8.5 Hz), 4.55 (s, 2H), 3.81 (s, 3H), 3.69 (t, 2H, J= 5.7 Hz), 2.77 (t, 2H, J= 5.5Hz), 1.42 (s, 9H).

Step E: 2-tert-Butyl 8-methyl 5-methyl-l,3,4,5-tetrahydro-2H-pyrido[4,3- b] indole~2,8-dicarboxylate

NaH (60% in oil) (6.4 g, 160 mmol) was slowly added into a solution of 2-tert-butyl 8-methyl l,3,4,5-tetrahydro-2H-pyrido[4,3-£>]indole-2,8-dicarboxylate(6.3 g, 20 mmol) in DMF at O⁰C, followed by addition of iodomethane (10 mL, 160 mmol). The reaction mixture was stirred overnight at room temperature. DMF was evaporated and the product was extracted with CΗ₂CI₂ and washed with water to obtain 11 g of crude product, which was carried over to the next step. ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.49 (s, 9 H) 2.82 (s, 3 H) 3.65 (s, 3 H) 3.84 (s, 3 H) 3.93 (s, 3 H) 7.27 (d, J=8.79 Hz, 1 H) 7.89 (d, J=8.59 Hz, 1 H) 8.21 (s, 1 H).

Step F: Methyl 5-methyl-2,3,4,5-tetrahydro-lH-pyrido [4,3-6] indole-8- carboxylate

2-tert-Butyl 8-methyl 5-methyl-l,3,4,5-tetrahydro-2H-pyrido[4,3-6]indole~2,8- dicarboxylate (3.4 g, 10 mmol) was dissolved in (15 mL) CH₂Cl₂, TFA (15 mL) was added and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated and lyophilized to yield 3.4 g of crude product as TFA salt, which was carried over to the next step. ¹H NMR (400 MHz, METHANOL-D4) δ 3.13 - 3.21 (m, 2 H) 3.66 (t, /=6.25 Hz, 2 H) 3.74 (s, 4 H) 3.90 (s, 4 H) 4.48 (dd, 1 H) 7.47 (dd, J=8.79, 0.59 Hz, 1 H) 7.89 (dd, /=8.69, 1.66 Hz, 1 H) 8.21 (d, J=1.56 Hz, 1 H)-

Step G: Methyl 5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lJ3- pyrido[4,3-δ]indole-8-carboxylate

Methyl 5-methyl-2,3,4,5-tetrah.ydro-lH-pyrido[4,3-έ]indole-8-carboxylate (1.5 g, 4.2 mmol) was dissolved in a mixture of CΗ₂Cl₂:Me0Η (1:1, 40 mL), triethylamine (1.2 mL, 8.4 mmol) was added, followed by the addition of tetrahydro-4H-pyran-4-one (0.8 mL, 8.4 mmol) and NaBHjCN (528 mg, 8.4 mmol). The reaction mixture was stirred at 50 ⁰C overnight, concentrated and extracted with CΗ₂CI₂, washed with NaHCOs then brine. The crude product (1.7g) was carried over to the next step. MS (APPI) (M+H)⁺= 329.10.

Step H: 5-Methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH- pyrido[4,3-Z>]indole-8-carboxylic acid

Methyl 5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3- Z>]indole-8-carboxylate(1.7 g, 5 mmol) was dissolved in a mixture of TΗF/MeOΗ/Η₂O (1:1:1), KOH (1.4 g, 25 mmol) was added and the reaction was stirred at room temperature for 3 hours. The reaction mixture was neutralized with 5N HCl to pH ~ 5.0, concentrated and used as crude product (1.5 g) for the next step. MS (APPI) (M+H)⁺=315.11. Step I: tert-Butyl 3-[(cyclopropylamino)carbonyl]piperidine-l-carboxylate

l-(fer£-Butoxycarbonyl)-3-piperidine carboxylic acid (500 mg, 2.2 mmol) and cyclopropyl amine (189 mg, 3.3 mmol) were dissolved in dry DMF (10 mL), NN- diisopropylethylamine(1.5 mL, 8.8 mmol) was added and the mixture was cooled down to 0 ⁰C. HATU (Ig, 2.64 mmol) was added in portion and the reaction was stirred overnight at room temperature. The reaction was concentrated and the product was extracted with EtOAc and washed with ΝaHCθ3, water then brine. The crude product (1.0 g) was carried over to the next step. ¹H NMR (400 MHz₃

CHLOROFORM-D) δ 0.42 - 0.50 (m, 2 H) 0.70 - 0.76 (m, 2 H) 0.76 - 0.83 (m, 2 H) 0.85 - 0.95 (m, 2 H) 1.44 (s, 9 H) 2.66 - 2.76 (m, 4 H) 3.17 (q, J=7.42 Hz₅ 1 H) 3.71 (ddd, /=13.52, 7.13, 6.88 Hz, 1 H).

Step J: iV-Cyclopropylpiperidine~4-carboxamide (TFA salt)

tert-Butyl 3-[(cyclopropylamino)carbonyl]piperidine-l-carboxylate (Ig, 3.7 mmol) was dissolved in 10 ml of CH₂CI₂, 10 mL of TFA were added and the reaction was stirred at room temperature for 2 hours. The reaction mixture was concentrated and lyophilized to obtain the title compound as TFA salt (1.0 g), which was carried over to the next step.

Example 2 iV-Cyclopropyl-l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro- lJϊ-pyrido[4,3-δ]indol-8-yl]carbonyI}pyrrolidine-3-carboxamide

Step A: iV-Cyclopropyl-l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5- tetrahydro-lH-pyrido[4,3-£]indol-8-yl]carbanyl}pyrroHdine-3-carboxamide

Following the procedure for Step A in Example 1, using 5-methyl-2-(tetrahydro-2H- pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indole-8-carboxylic acid (100 mg, 0.32 mmol), N-cyclopropylpyrrolidine-S-carboxamide (HCl salt) (122 mg, 0.64 mmol) (see following steps B and C for preparation), N_^N-diisopropylethylamine (0.3 mL, 1.3 mmol) and ΗATU (146 mg, 0.38 mmol) in (10 mL) DMF. The crude product was purified by LCMS using low pΗ column 10-30% acetonitrile gradient to give the title compound as a white solid (TFA salt, 10 mg, 7%). ¹H ΝMR (400 MHz, METHAΝOL-D4) δ 0.36 - 0.45 (m, 2 H) 0.47 - 0.54 (m, 2 H) 0.70 (dd, J=21.78, 6.93 Hz, 2 H) 1.28 (s, 3 H) 1.85 - 2.00 (m, 2 H) 2.02 - 2.27 (m, 4 H) 2.57 - 2.73 (m, 1 H) 2.85 - 3.09 (m, 1 H) 3.50 (t, /=12.40 Hz, 2 H) 3.55 - 3.73 (m, 4 H) 3.74 (s, 3 H) 3.75 - 3.86 (m, 2 H) 4.12 (dd, J=I 1.82, 4.00 Hz, 2 H) 7.38 - 7.44 (m, 1 H) 7.45 - 7.52 (m, 1 H) 7.72 (s, 1 H); MS (APPI) (M+H)⁺=451.2

Step B: tert-Butyl 3-[(cyclopropylamino)carbonyl]pyrrolidine-l-carboxylate

l-^ert-Butoxycarbony^pyrrolidine-S-carboxylic acid (730 mg, 3.4 mmol) and cyclopropyl amine (388 mg, 6.8 mmol) were dissolved in (10 mL) of dry DMF, (2.4 mL, 13.6 mmol) NN-diisopropylethylamine was added and the mixture was cooled down to 0 ⁰C. (1.6 g, 4.1 mmol) of HATU was added portionwise and the reaction was stirred overnight at room temperature. The reaction was concentrated and the product was extracted with EtOAc and washed with NaHCθ₃, water then brine. The crude product (1.0 g) was carried over to the next step.

Step C: iV-Cyclopropylpyrrolidine-S-carboxamide (HCl salt)

tert-BvAyl 3-[(cyclopropylarnino)carbonyl]pyrrolidine-l-carboxylate (800 mg, 3.4 mmol) was dissolved in 15 ml of 4N HCl in dioxane, the reaction was stirred at room temperature for 3 hours. The reaction mixture was concentrated and lyophilized to obtain the title compound as HCl salt (2.5 g, crude), which was carried over to the next step.

Example 3 Λ^r-Cyclopropyl-2-(l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro- lH-pyrido[4,3-u>]indol-8-yl]carbonyl}azetidm-3-yl)acetamide

Step A: iV-Cyclopropyl-2-(l-{[5-methyl-2-(tetrahydro-2iϊ-pyran-4-yI)-2,3,4,5- tetrahydro-liϊ-pyrido[4,3-6]indol-8-yl]carbonyl}azetidin-3-yl)acetamide

Following the procedure for Step A in Example 1, using 5-methyl-2-(tetrahydro-2H- pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-Z?]indole-8-carboxylic acid (30 mg, 0.1 romol), 2-azetidin-3-yl-N-cyclopropylacetamide (HCl salt) (38 mg, 0.2 mmol) (see following_.steps B and C for preparation), NN-diisopropylethylamine (70 uL, 0.4 mmol) and HATU (46 mg, 0.12 mmol) in DMF (5 mL), after purification by LCMS using low pH column 10-30% acetonitrile gradient, provided the title compound as a white solid (TFA salt, 30 mg, 53%). ¹H ΝMR (400 MHz, METHAΝOL-D4) δ 0.41 - 0.49 (m, 2 H) 0.65 - 0.74 (m, 2 H) 1.88 - 1.99 (m, 2 H) 2.12 - 2.25 (m, 2 H) 2.51 (dd, /=7.52, 4.39 Hz, 2 H) 2.58 - 2.66 (m, 1 H) 3.23 - 3.29 (m, 5 H) 3.41 - 3.62 (m, 4 H) 3.67 - 3.74 (m, 2 H) 3.75 (s, 3 H) 4.13 (dd, J=12.99, 4.98 Hz, 2 H) 4.49 - 4.57 (m, 2 H) 4.70 - 4.78 (m, 1 H) 7.46 - 7.50 (m, 1 H) 7.50 - 7.55 (m, 1 H) 7.84 (d, /=0.98 Hz, 1 H); MS (APPI) (M+H)⁺=451.2

Step B: tert-Butyl 3-[2-(cyclopropylamino)-2-oxoethyl]azetidine-l-carboxylate

l-(fert-Butoxycarbonyl)azetidin-3-yi]acetic acid (1 g, 5 mmol) and cyclopropyl amine (570 mg, 10 mmol) were dissolved in dry DMF (10 mL), NN-diisopropylethylamine (3.5 mL, 20 mmol) was added and the mixture was cooled down to 0 ⁰C. HATU (2.3 g, 6 mmol) was added portionwise and the reaction was stirred overnight at room temperature. The reaction was concentrated and the product was extracted with EtOAc and washed with NaHCO₃, water then brine. The crude product (3.0 g) was carried over to the next step. ¹H NMR (400 MHz, CHLOROFORM-D) δ 0.44 - 0.51 (m, 2 H) 0.69 - 0.76 (m, 2 H) 1.40 (s, 9 H) 2.42 (d, /=7.81 Hz, 2 H) 3.18 (q, J=7.42 Hz, 2 H) 3.66 - 3.74 (m, 2 H) 4.05 (t, /=8.59 Hz, 2 H).

Step C: Z-Azetidin-S-yl-iV-cyclopropylacetamide (HCl salt)

tert-Butyl 3-[2-(cyclopropylamino)-2-oxoethyl]azetidine-l-carboxylate (1.3 g, 5 mmol) was treated with 15 ml of 4N HCl in dioxane at room temperature for 3 hours. The reaction mixture was then concentrated, and lyophilized to provide the title compound as its HCl salt (2.63 g, crude), which was carried over to the next step. Example 4

N-Cyclopropyl-l-flS-methyl-Z-Ctetrahydro-ZH-pyran^-y^-Z_jS^_jS-tetrahydro- lH-pyrido[4,3-b]indol-8-yl]carbonyl}azetidine-3-carboxamide

Following the procedure for Step A in Example 1, using 5-memyl-2-(tetrahydro-2H- pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-&]indole-8-carboxylic acid (100 mg, 0.32 mmol), azetidine-3-carboxylic acid (32 mg, 0.32 mmol), N^V- diisopropylethylamine (0.3 mL, 1.3 mmol) and ΗATU (146 mg, 0.38 mmol) in (5 mL) DMF. The reaction was stirred at room temperature for 2 hours, followed by addition of cyclopropylamine (27 mg, 0.48 mmol) and ΗATU (146 mg, 0.38 mmol) . The reaction mixture was stirred overnight. The crude product was purified by LCMS using high pΗ column 10-30% acetonitrile gradient to give the title compound as a white solid (TFA salt, 2 mg, 1%). MS (APPI) (M+Η)⁺= 437.3

Example 5

(3_JR)-l-{[2-Cyclopentyl-5-(2-furylsulfonyl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-

6]indol-8-yl]carbonyl}-iV-cyclopropylpiperidine-3-carboxamide

Step A. (3i?)-l-{[2-Cyclopentyl-5-(2-furyIsulfonyl)-2,3,4,5-tetrahydro-lH- pyrido[4,3-έ]indol-8-yl]carbonyl}-iV-cyclopropylpiperidme-3-carboxamide

NaH (0.19 g, 4.8 mmol) was added to a solution of (3R)-l-[(2-cyclopentyl-2,3,4,5- tetrahydro-lH-pyrido^jS-δJindol-δ-yOcarbonylJ-N-cyclopropylpiperidine-S- carboxamide (0.21 g, 0.48 mmol) in DMF (15 mL) under nitrogen atmosphere. The reaction mixture was stirred for 3 hrs. Furan-2-sulfonyl chloride (0.80 g, 4.8 mmol) was added and the reaction mixture was stirred for 2 hrs. The reaction mixture was slowly added to a mixture OfNaHCO₃ (0.40 g, 4.8 mmol) and MeOH (80 mL) at - 78°C. The resulting mixture was allowed to warm to ambient temperature and the solvent was concentrated. CH₂CI₂ (20 mL) was added and the precipitated salts were filtered. The filtrate was concentrated and the product was purified by preparative reverse-phase HPLC to provide the TFA salt of the title compound as white solid (56 mg, 17 %). [α]_D -21.8° (c = 1.20, CD₃OD); ¹H NMR (400 MHz, CD₃OD) δ 0.19 - 0.85 (m, 2 H), 1.57 - 2.07 (m, 10 H), 2.19 - 2.41 (m, /=10.55 Hz, 2 H), 3.05 - 3.26 (m, 1 H), 3.45 - 3.68 (m, 1 H), 3.70 - 3.88 (m, /=7.81, 7.81 Hz, 2 H), 4.30 - 4.54 (m, 2 H), 4.63 - 4.87 (m, 1 H), 6.62 (dd, J=3.71, 1.76 Hz, 1 H), 7.44 (dd, J=8.69, 1.66 Hz₅ 1 H), 7.49 (dd, /=3.71, 0.78 Hz, 1 H), 7.63 (d, /=1.17 Hz, 1 H), 7.73 (dd, /=1.76, 0.78 Hz, 1 H), 8.12 (dd, /=8.69, 0.49 Hz, 1 H); MS (ESI) QVB-H)⁺ 565.3.

Step B. Methyl 2,3,4,5-tetrahydro-liϊ-pyrido[4,3-έ]mdole-8-carboxylate

2-tert-Butyl 8-methyl 1 ,3,4,5-tetrahydro-2H-pyrido[4,3-Z»]indole-2,8-dicarboxylate (5.4 g, 16 mmol) was added to TFA (40 mL) in CH₂Cl₂ (40 mL). The solution was stirred for 1 hr. and concentrated to dryness. The residue was recovered in water (50 mL), stirred at 0⁰C for 1 hr. and filtered. The solid was thoroughly washed with ether (2 x 150 mL), filtered and dried to provide the pure TFA salt of the title compound as pink solid (5.6 g, 99 %). MS (ESI) (M+H)⁺ 231.0.

Step C. Methyl l-cyclopentyl^^^jS-tetrahydro-lH-pyrido^^-δJindole-S- carboxylate

Cyclopentanone (5.6 mL, 63 mmol) was added to a solution of methyl 2,3,4,5- tetrahydro-lH-pyrido[4,3-Z>]indoIe-8-carboxylate (5.6 g, 16 mmol) in EtOH (80 mL). The solution was stirred for 1 hr. and NaBH(OAc)₃ (5.3 g, 25 mmol) was added. The reaction mixture was stirred for 4 hrs. and the solvent was concentrated. The product was purified by normal-phase MPLC using 2% Et₃N, 5% MeOH and 10% acetone in DCM to provide the title compound as pale-yellow solid (4.56 g, 94 %). MS (ESI) (M+H)⁺ 299.1.

Step D. 2-CycIopentyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-Z>]indole-8-carboxyIic acid

MeOH (15 mL) was added to a mixture of methyl 2-cyclopentyl-2,3,4,5-tetrahydro- lH-pyrido[4,3-£]indole-8-carboxylate (4.5 g, 15 mmol) and NaOH 2M (50 mL). The reaction mixture was heated to 85°C upon clear solution obtained and was concentrated to 50 mL. The solution was neutralized with concentrated HCl at O⁰C. The precipitate was filtered, washed with ether and dried to provide the pure title compound as pink solid (4.25 g, 98 %). MS (ESI) (M+Η)⁺ 285.1. Step E. Ethyl (3_JR)-l-[(2-cyclopentyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-6]indol-8- yl)carbonyl]piperidine-3-carboxylate

HATU (1.9 g, 5.0 mmol) and ethyl (3ϋ)-piperidine-3-carboxylate (0.67 g, 4.2 mmol) were added to a solution of cyclopentyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-ό]indole-8- carboxylic acid (1.1 g, 3.8 mmol) and DIPEA (1.7 niL, 9.6 mmol) in DMF (25 mL). The reaction mixture was stirred for 2 hrs. and was then concentrated. The product was purified by normal-phase MPLC using 2% Et₃N, 5% MeOH and 10% acetone in DCM to provide the title compound as colorless oil (1.6 g, 97 %). ¹H NMR (400 MHz, CD₃OD) δ 1.27 - 1.38 (m, 3 H)₃ 1.47 - 1.70 (m, 6 H), 1.70 - 1.87 (m, 5 H), 1.94 - 2.18 (m, 3 H), 2.85 - 3.07 (m, 6 H), 3.16 - 3.53 (m, 2 H), 3.75 - 3.88 (m, 2 H), 4.00 - 4.22 (m, 2 H), 7.12 (dd, J=8.30, 1.46 Hz, 1 H), 7.33 (dd, J=8.40, 0.59 Hz, 1 H), 7.48 (s, 1 H); MS (ESI) (M+H)⁺ 424.0.

Step F. (3jR)-l-[(2-Cyclopentyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-6]indol-8- yl)carbonyl]piperidine-3-carboxylic acid

Following the procedure for Step D in Example 5, using ethyl (3i?)-l-[(2-cyclopentyl- 2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indol-8-yl)carbonyl]piperidine-3-carboxylate (1.5 g, 3.6 mmol) provided the title compound as white solid (1.43 g, 99 %). ¹H NMR (400 MHz, CD₃OD) δ 1.66 - 1.81 (m, /=3.91 Hz, 3 H), 1.89 (s, 8 H), 2.20 - 2.47 (m, 3 H), 2.87 - 3.02 (m, 1 H), 3.14 - 3.27 (m, 2 H), 3.58 - 3.89 (m, 6 H), 4.43 - 4.60 (m, 1 H), 7.19 (d, /=8.59 Hz, 1 H), 7.39 (d, /=8.40 Hz, I H), 7.60 (s, 1 H), 8.44 (s, 1 H); MS (ESI) (MH-H)⁺ 396.2. Step G. (3i?)-l-[(2-Cyclopentyl-2,3,4,5-tetrahydro-lH^r-pyrido[4,3-6]indol-8- yl)carbonyl]-Λ^r-cyclopropylpiperidine-3-carboxamide

HATU (1.6 g, 4.3 mmol) and cyclopropylamine (0.23 g, 3.9 mmol) were added to a solution of (3R)- 1 -[(2-cyclopentyl-2,3,4,5-tetrahydro- lH-pyrido[4,3 -£>]indol-8- yl)carbonyl]piperidine-3-carboxylic acid (1.4 g, 3.6 mmol) and DEPEA (1.5 mL, 9.0 mmol) in DMF (40 mL) at 0⁰C. The reaction mixture was allowed to warm to ambient temperature and stirred for 3 hrs. The solvent was concentrated and the product was purified by normal-phase MPLC using 2% Et₃N, 5% MeOH and 10% acetone in DCM to provide the title compound as white solid (1.5 g, 98 %). [α]_D -19.5° (c = 1.12, CD₃OD); ¹H NMR (400 MHz, CD₃OD) δ 0.57 - 0.80 (m, 4 H) 1.67 - 2.03 (m, 14 H) 2.22 - 2.43 (m, 2 H) 3.10 - 3.27 (m, J=7.23, 7.23, 7.23 Hz, 4 H) 3.55 (td, /=11.33, 5.08 Hz, 1 H) 3.72 - 3.88 (m, J=8.01, 8.01 Hz, 1 H) 3.88 - 4.03 (m, J=I 1.82, 5.18 Hz, 1 H) 4.39 (d, /=14.45 Hz, 1 H) 4.75 (d, /=13.48 Hz, 1 H) 7.20 (dd, /=8.40, 1.56 Hz, 1 H) 7.41 (d, /=8.40 Hz, 1 H) 7.58 (s, 1 H); MS (ESI) (M+H)⁺ 435.3.

Example 6

(3i?)-l-{[2-CyclopentyI-5-(ethylsulfonyl)-2,3,4,5-tetrahydro-li3^r-pyrido[4,3-

£]indol-8-yl]carbonyl}-iV-cyclopropylpiperidine-3-carboxamide

Following the procedure for Step A in Example 5, using ethyl sulfonyl chloride (0.43 mL, 4.6 mmol) provided the TFA salt of the title compound as white solid (76 mg, 25 %). [α]_D -21-8° (c = 1.24, CD₃OD); ¹H NMR (400 MHz, CD₃OD) δ 0.29 - 0.59 (m, 2 H), 0.64 - 0.81 (m, 2 H)₃ 1.22 (t, /=7.42 Hz, 3 H), 1.63 - 2.06 (m, 10 H), 2.22 - 2.43 (m, 3 H), 3.06 - 3.25 (m, J=I 1.52, 11.52 Hz, 2 H), 3.37 - 3.59 (m, /=7.42, 7.42, 7.42 Hz, 6 H), 3.58 - 3.73 (m, 1 H), 3.73 - 3.94 (m, 1 H), 4.31 - 4.56 (m, 2 H), 4.71 - 4.84 (m, 1 H), 7.42 (dd, 7=8.69, 1.66 Hz, 1 H), 7.68 (d, J=0.98 Hz, 1 H), 8.05 (d, /=8.59 Hz, 1 H); MS (ESI) (M+H)⁺ 527.3.

Example 7

(S^-l-fP-Cyclopentyl-S-CmethylsulfonyO-ljS^jS-tetrahydro-lH-pyrido^^- a]indol-8-yl]carbonyl}-7V-cyclopropylpiperidine-3-carboxainide

Following the procedure for Step A in Example 5, using methyl sulfonyl chloride (0.36 mL, 4.6 mmol) provided the TFA salt of the title compound as white solid (40 mg, 13 %). [αb -22.9° (c = 1.22, CD₃OD); ¹H NMR (400 MHz, CD₃OD) δ 0.23 - 0.83 (m, 5 H), 1.25 - 1.64 (m, /=30.66 Hz, 2 H), 1.64 - 2.05 (m, /=51.66, 6.54 Hz, 6 H), 2.20 - 2.38 (m, 3 H), 2.37 - 2.77 (m, 1 H), 2.91 - 3.24 (m, 4 H), 3.32 - 3.60 (m, 5 H), 3.58 - 3.75 (m, 1 H), 3.74 - 3.90 (m, 1 H), 3.88 - 4.10 (m, 1 H), 4.33 - 4.55 (m, /=13.77, 13.77 Hz, 2 H), 4.71 - 4.85 (m, 2 H), 7.37 - 7.49 (m, 1 H), 7.58 - 7.73 (m, 1 H), 7.96 - 8.12 (m, 1 H); MS (ESI) (M+H)⁺ 513.3.

Example 8

(35)-l-{[2-Cyclopentyl-5-(ethylsulfonyl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-

6]indol-8-yl]carbonyl}-iV-cyclopropylpiperidine-3-carboxamide

Step A. (3S)-l-{ P-Cyclopentyl-S-CethylsulfonyO-Iβ^jS-tetrahydro-lH- pyrido^jS-^JindoI-S-yllcarbonylj-N-cyclopropylpiperidine-S-carboxamide

Following the procedure for Step A in Example 5, using (3iS)-l-[(2-cyclopentyl- 2,3,4,5-tetrahydro-lH-ρyrido[4,3-έ]indol-8-yl)carbonyl]-N-cyclopropylpiperidine-3- carboxamide (0.20 g, 0.46 mmol) and ethyl sulfonyl chloride (0.43 mL, 4.6 mmol) provided the TFA salt of the title compound as white solid (45 mg, 15 %). [α]p +21.1° (c = 1.33, CD₃OD); ¹H ΝMR (400 MHz, CD₃OD) δ 0.29 - 0.42 (m, 1 H), 0.43 - 0.57 (m, 1 H), 0.57 - 0.82 (m, 2 H), 1.22 (t, J=7.42 Hz, 3 H), 1.64 - 2.06 (m, 11 H), 2.23 - 2.40 (m, 2 H), 2.38 - 2.75 (m, 2 H), 3.07 - 3.24 (m, 1 H), 3.36 - 3.60 (m, J=7.42, 7.42, 7.42 Hz, 4 H), 3.60 - 3.75 (m, 1 H), 3.74 - 3.88 (m, 1 H), 3.91 - 4.08 (m, 1 H), 4.33 - 4.54 (m, 2 H), 4.70 - 4.88 (m, 2 H), 7.42 (dd, J=8.69, 1.66 Hz, 1 H), 7.68 (d, J=I.17 Hz, 1 H), 8.05 (dd, J=8.59, 0.59 Hz, 1 H); MS (ESI) (M+H)⁺ 527.3.

Step B. Ethyl (35)-l-[(2-cyclopentyl-2,3,4,5-tetrahydro-li?-pyrido[4,3-έ]indol-8- yl)carbonyl]piperidine-3-carboxylate

Following the procedure for Step E in Example 5, using ethyl (3S)-piperidine-3- carboxylate (0.18 g, 0.11 mmol) provided the title compound as white solid (0.29 g, 65 %). ¹HNMR (400 MHz, CD₃OD) δ 1.11 - 1.35 (m, 3 H), 1.45 - 1.70 (m, 6 H), 1.69 - 1.90 (m, 5 H), 1.97 - 2.15 (m, J=8.40, 4.30 Hz, 3 H), 2.79 - 3.05 (m, 6 H), 3.16 - 3.29 (m, 1 H), 3.32 - 3.50 (m, 1 H), 3.78 (s, 2 H), 3.95 - 4.29 (m, 2 H), 7.11 (dd, J=8.40, 1.56 Hz, 1 H), 7.33 (d, J=8.40 Hz, 1 H), 7.48 (s, 1 H); MS (ESI) (M+H)⁺ 424.0.

Step C. (35)-l-[(2-CyclopentyI-2,3,4,5-tetrahydro-lH-pyrido [4,3-6]indol-8- ytycarbonylJpiperidiiie-S-carboxylic acid

Following the procedure for Step F in Example 5, using ethyl (3S)-l-[(2-cyclopentyl- 2,3,4,5-tetrahydro-lH-pyrido[4,3-b]indol-8-yI)carbonyl]piperidine-3-carboxylate (0.28 g, 0.66 mmol) provided the title compound as white solid(0.25 g, 95 %). MS (ESI) (M+H)⁺ 396.2.

Step D. (35)-l-[(2-Cyclopentyl-2,3,4,5-tetrahydro-lff-pyrido[4,3-6]indol-8- yl)carbonyl]-Λ^r-cyclopropylpiperidine-3-carboxamide

Following the procedure for Step G in Example 5, using (3S)-l-[(2-cyclopentyl- 2,3 ,4,5-tetrahydro- lH-pyrido[4,3 -έ]indol-8-yl)carbonyl]piperidine-3 -carboxylic acid (0.25 g, 0.63 mmol) provided the title compound as white solid (0.12 g, 42 %). [α]_D +24.0° (c = 1.19, CD₃OD); ¹H NMR (400 MHz, CD₃OD) δ 0.39 - 0.57 (m, /=6.64 Hz, 1 H), 0.58 - 0.81 (m, J=14.06 Hz, 3 H), 1.65 - 2.01 (m, 14 H), 2.21 - 2.43 (m, 2 H), 3.05 - 3.29 (m, 4 H), 3.43 - 3.62 (m, 1 H), 3.71 - 3:88 (m, 1 H), 3.88 - 4.06 (m, 1 H), 4.38 (d, /=14.26 Hz, 1 H), 4.75 (d, 7=14.45 Hz, 1 H), 7.20 (dd, /=8.40, 1.56 Hz, 1 H), 7.41 (d, /=8.40 Hz, 1 H), 7.58 (s, 1 H); MS (ESI) (M+H)⁺ 435.3.

Example 9

(S^-l-IIδ-CEthylsulfony^^-^etrahydro-lJΪ-pyran^-y^^jS^jS-tetrahydro-lJϊ- pyrido[4,3-ά]indol-8-yl]carbonyl}-iV-methylpiperidine-3-carboxamide

Step A (3i)-l-{[5-(Ethylsulfonyl)-2-(tetrahydro-2iT-pyran-4-yl)-2,3,4,5- tetrahydro-LET-pyrido [4,3-Z>] indol-8-yl] carbonyl}-iV-methylpiperidine-3- carboxamide

Following the procedure for Step G in Example 5, using (3S)-l-{[5-(ethylsulfonyl)-2- (tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetraliydro-lH-pyrido[4,3-δ]indol-8- yl]carbonyl}piperidine-3-carboxylic acid hydrochloride (125 mg, 0.20 rnmol) (see following steps B, and C for preparation), methylamine in TΗF (2.0 M, 0.2 mL, 0.40 mmol), N^V-diisopropylethylamine (77 mg, 104 uL, 0.60 mmol) and ΗATU (99 mg, 0.26 mmol) in DMF (5 mL). The crude product was purified by reverse-phase ΗPLC using high pΗ column 20-40% MeCΝ/Η₂O to give the title compound as a white solid (61 mg, 59%). ¹H NMR (400 MHz, METHANOL-D4) δ 1.21 (t, /=7.42 Hz, 3 H), 1.40 - 1.83 (m, 3 H), 1.83 - 2.04 (m, 5 H), 2.16 (m, 2 H), 2.28 - 2.52 (m, 1 H), 2.59 (s, 1.5 H), 2.73 (s, 1.5 H), 2.88 - 3.22 (m, 1 H), 3.37 - 3.58 (m, 8 H), 3.61 - 3.80 (m, 2 H), 4.12 (dd, ./=11.62, 4.20 Hz, 2 H), 4.34 - 4.84 (m, 2 H), 7.42 (dd, /=8.69, 1.66 Hz, 1 H), 7.66 (d, J=0.98 Hz₅ 1 H), 8.04 (d, J=8.59 Hz, 1 H); MS (APPI) (M+H)⁺= 517.3; [ccfo: +30.7 ° (c 0.31, MeOH).

Step B: Ethyl (3»S)-l-{[5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5- tetrahydro-lfT-pyrido^jS-^lindol-S-ylJcarbonylJpiperidine-S-carboxylate

Following the procedure for Step E in Example 5, using 5-(ethylsulfonyl)-2- (tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-&]indole-8-carboxylic acid hydrochloride (1.29 g, 3.0 mmol), ethyl (3S)-piperidine-3-carboxylate (0.71 g, 4.5 mmol), NN-diisopropylethylamiαe (1.16 g, 1.56 mL, 9.0 mmol) and ΗATU (1.48 g, 3.9 mmol) in DMF(15 mL). The crude product was purified by MPLC on silica gel using EtOAc/MeOΗ (10:1) to give the title compound as a white solid (1.58 g, 99%). ^{' 1}H ΝMR (400 MHz, METHAΝOL-D4) δ 1.03 - 1.16 (m, 2 H), 1.15 (t, /=7.32 Hz, 3 H), 1.26 (dd, /=12.30, 6.64 Hz, 2 H), 1.46 - 1.88 (m, 6 H), 1.90 - 1.99 (m, 2 H), 2.01 - 2.14 (m, 1 H), 2.49 - 2.68 (m, 1 H), 2.77 - 2.89 (m, 1 H), 2.98 - 3.16 (m, 4 H), 3.32 - 3.51 (m, 6 H), 3.85 (s, 2 H), 3.92 - 4.23 (m, 4 H), 7.33 (d, /=8.40 Hz, 1 H), 7.56 (s, 1 H), 8.00 (d, /=8.59 Hz, 1 H); MS (APPI) (M+H)⁺= 532.3.

Step C: (35)-l-{[5-(EthylsuIfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5- tetrahydro-lH-pyrido[4,3-δ]indol-8-yl]carbonyl}piperidine-3-carboxylic acid

Lithium hydroxide (0.14 g, 5.77 mmol) was added to a solution of ethyl (3S)-l-{[5- (ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3- &]indol-8-yl]carbonyl}piperidine-3-carboxylate (1.54 g, 2.88 mmol) in 50 mL of THF-H₂O (7:3). Stirring for 2 h at room temperature, the reaction mixture was neutralized by 2NHC1 until pH= 5-6. After concentration and dried in vacuo, a white solid (1.80 g, 100%) was obtained as its hydrochloride saltof the crude product, which was used directly in next step without further purification. MS (APPI) (M+H)⁺= 504.3.

Example 10

(35)-Λ-Ethyl-l-{[5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3₅4,5- tetrahydro~lH-pyrido[4,3-6]mdol-8-yl]carbonyl}piperidine-3-carboxamide

Following the procedure for Step G in Example 5, using (35)-l-{[5-(ethylsulfonyl)-2- (tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indol-8- yl]carbonyl}piperidine-3-carboxylic acid hydrochloride (125 mg, 0.20 mmol), ethylamine in TΗF (2.0 M, 0.2 mL, 0.40 mmol), N^V-diisopropylethylamine (77 mg, 104 uL, 0.60 mmol) and ΗATU (99 mg, 0.26 mmol) in DMF (5 mL). The crude product was purified by reverse-phase ΗPLC using high pΗ column 20-40% MeCΝ/Η₂O to give the title compound as a white solid (84 mg, 79%). ¹H NMR (400 MHz, METHANOL-D4) δ 0.93 - 1.17 (m, 3 H), 1.22 (t, /=7.32 Hz, 3 H), 1.41 - 1.65 (m, 1 H), 1.66 - 1.84 (m, 2 H), 1.93 (d, /=19.92 Hz, 4 H), 2.18 (m, 2 H), 2.26 - 2.53 (m, 1 H), 2.88 - 3.23 (m, 3 H), 3.38 - 3.62 (m, 8 H), 3.61 - 3.83 (m, 2 H), 3.88 - 4.06 (m, 1 H), 4.13 (d, /=12.11 Hz, 2 H), 4.37 - 4.80 (m, 2 H), 7.44 (d,/=7.03 Hz, 1 H), 7.67 (s, 1 H), 8.05 (d, /=8.59 Hz, 1 H); MS (APPI) (M+H)⁺= 531.2; [α]_D: +30.0 ° (c 0.38, MeOH)..

Example 11

(S^-l-ltS-CEthylsulfonylJ-Z-^etrahydro^H-pyran^-yl^Z_jS^_jS-tetrahydro-tfiT- pyrido[4,3-έ]indol-8-yl]carbonyl}-iV-isopropylpiperidine-3-carboxamide

Following the procedure for Step G in Example 5, using (35)-l-{[5-(ethylsulfonyl)-2- (tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indol-8- yl]carbonyl}piρeridine-3-carboxylic acid hydrochloride (125 mg, 0.20 mmol), isopropylamine (24 mg, 0.40 mmol), NN-diisopropylethylamine (77 mg, 104 uL, 0.60 mmol) and ΗATU (99 mg, 0.26 mmol) in DMF (5 mL). The crude product was purified by reverse-phase ΗPLC using high pΗ column 20-40% MeCΝ/Η₂O to give the title compound as a white solid (96 mg, 88%). ¹H NMR (400 MHz, METHANOL-D4) δ 0.91 - 1.17 (m, 6 H), 1.21 (t, /=7.32 Hz, 3 H), 1.41 - 1.83 (m, 2 H), 1.84 - 2.03 (m, 5 H), 2.11 - 2.22 (m, 2 H), 2.25 - 2.53 (m, 1 H), 2.89 - 3.22 (m, 1 H), 3.36 - 3.61 (m, 9 H), 3.62 - 3.86 (m, 2 H), 3.89 - 4.06 (m, 1 H), 4.12 (dd, J=11.62, 4.20 Hz, 2 H), 4.35 - 4.79 (m, 2 H), 7.43 (dd, /=8.59, 1.56 Hz, 1 H), 7.66 (d, /=0.98 Hz, 1 H), 8.04 (d, /=8.59 Hz, 1 H); MS (APPI) (M+H)⁺= 545.2; [α]_D: +27.1 ° (c 0.31, MeOH).

Example 12

(3_ιS)-Λ^r-Cyclopropyl-l-{[5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5- tetrahydro-Hr-pyrido[4,3-6]indol-8-yl]carbonyl}piperidine-3-carboxamide

Following the procedure for Step G in Example 5, using (3S)-l-{[5-(ethylsulfonyl)-2- (tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-ό]indol-8- yl]carbonyl}piperidine-3-carboxylic acid hydrochloride (125 mg, 0.20 mmol), cyclopropylamine (23 mg, 0.40 mmol), NN-diisopropylethylamine (77 mg, 104 uL, 0.60 mmol) and ΗATU (99 mg, 0.26 mmol) in DMF (5 mL), after purification by reverse-phase HPLC using high pH column 20-40% MeCNZH₂O, provided the title compound as a white solid to give (88 mg, 81%). ¹H NMR (400 MHz, METHANOL- D4) 5 0.28 - 0.41 (m, 1 H), 0.43 - 0.56 (m, 1 H), 0.58 - 0.79 (m, 2 H), 1.21 (t, J=7.32 Hz, 3 H), 1.39 - 1.82 (m, 2 H), 1.84 - 2.04 (m, 4 H), 2.10 - 2.21 (m, 2 H), 2.25 - 2.73 (m, 2 H), 2.92 - 3.22 (m, 2 H), 3.36 - 3.60 (m, 8 H), 3.59 - 3.81 (m, 2 H), 3.89 - 4.07 (m, 1 H), 4.12 (dd, J=I 1.52, 3.91 Hz, 2 H), 4.35 - 4.79 (m, 2 H), 7.42 (dd, 7=8.59, 1.37 Hz, 1 H), 7.66 (s, 1 H), 8.04 (d, /=8.59 Hz, 1 H); MS (APPI) (M+H)⁺= 543.2; [α]_D: +26.9 ° (c 0.29, MeOH).

Claims

What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:

Wherein

selected from piperidine, pyrrolidine, azetidine and azepane;

R¹ is selected from C^aUcyl and C_3-6cycloalkyl;

R² is selected from -H, C_1-6alkyl, C_2-6alkenyl, -C(=O)-NR⁹R¹⁰, -S(=O)₂- NR⁹R¹⁰, -S(=O)₂-C_1-6alkyl, -S(=O)₂-C_6-10aryl, -S(=O)₂-C_3-5heteroaryl, -C(=O> Ci-βalkyl;

Ci^alkyl, C₂.₆allcenyl, -S(=O)₂-Ci_-6alkyl, -S(=0)₂-C_6-ioaryl, -S(=O)₂-C_3-5heteroaryl, -C(O)- Ci-βalkyl;

used in defining R² is optionally substituted with one or more group selected from -OR, R, -CO₂H, -CO₂-R; -SO₂-R; halogen, -NO₂, -OH, -NH₂, -NHR, -C(=O)-NH₂, and -C(=O)-NHR;

R³ is selected from Cs.gheterocycloalkyl, C_3-6heterocycloalkyl-Ci_-4alkyl, C_3-6cycloalkyl, C₃.₆cycloalkyl-C_1-4alkyl, Ci_-6alkyl, C_2-6alkenyl, C_6-ioaryl-Ci_-4alkyl, C_3- 6heteroaryl-Ci_-4alkyl, -C(=O)-Ci_-6alkyl, -C(=O)-C_3-6cycloalkyl and -CC=NH)-C_1- βalkyl, wherein said Cs-βheterocycloalkyl, C_3-6heterocycloalkyl-Ci-₄aIkyl, C_3-6cycloalkyl, C_3-6cycloalkyl-Ci_-4alkyl, Ci-βalkyl, C_2-6alkenyl, C₆-ioaryl-Ci_-4alkyl, C_{3- 6}heteroaryl-C_1-4alkyl, -C(=O)-Ci_-6alkyl, -C(=O)-C_3-6cycloalkyl and -CC=NH)-C_1- βalkyl used in defining R³ is optionally substituted with one or more groups selected from -OR, R, NO₂, -CO₂H, -CO₂-R; -SO₂-R; halogen; -OH; -NH₂; -NHR, -C(=0> NH₂, and -C(=O)-NHR;

R is Ci-βalkyl; and

R⁹ and R¹⁰ are independently selected from -H, C_halky! Cg-ioaryl, Cβ-ioaryl- C_1-4alkyl,

C_2-6alkenyl, C_3-6cycloalkyl, and C₃.₆cycloalkyl-Ci-4alkyl; N,N-di(Ci_-4alkyl)amido-Ci_-6alkyl, hydroxy-Ci-βalkyl and Ci_-6alkoxy-Ci.₆alkyl.

2. A compound as claimed in claim 1, wherein R² is selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, t-butyl, allyl, -S(=O)₂-CH₃, -SC=O)₂-CH₂CH₃, 2-methoxyethyl, tetrahydropyran-4-yl-methyl, 1-propylsulfonyl, methylsulfonyl, ethylsulfonyl, cyclopropylsulfonyl, phenyl, phenylsulfonyl, 2-(methoxycarbonyl)-phenylsulfonyl; 2-(hydroxycarbonyl)- phenylsulfonyl, 1 -methyl- 1 H-imidazol-4-yl-sulfonyl, lH-imidazol- 1 -yl-sulfonyl, furylsulfonyl, (5-methyIisoxazol-4-yl)sulfonyl, morpholin-4-yIcarbonyl, 4-amino- phenyl, -CH₂-C(=O)-N(CH₃)₂, -C(=O)-N(CH₃)₂, -S(=O)₂-N(CH₃)₂, -S(O)₂- NHCH₂CH₃, -CC=O)-CH₂CH₂CH₃, -CH₂-C(O)-OCH₃, -CH₂-C(O)-OCH₂CH₃, - CH₂-CO₂H, benzyl, 4-aminobenzyl, 4-nitrobenzyl, 4-methylsulfonyl-benzyl, 4- methylthio-benzyl, 4-acetylamino-benzyl, 4-methoxy-benzyl, 4-ethoxy-benzyl, 2,6- difluorobenzyl, (6-chloro-l,3-benzodioxol-5-yl)methyl, (5-ethoxycarbonyl)-fur-2-yl- methyl, (2-methyl-l,3-thiazol-4-yl)-methyl, (5-methyl-isoxazol-4-yl)-methyl, pyridin- 2-ylmethyl, cyclobutylmethyl, and cyclopropylmethyl;

R³ is selected from ethyl, isopropyl, propyl, 2-methy-propyl, 1-butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 2-pyrimidmyl, 1-iminoethyl, 2-pyridinyl, 3,4,5,6- tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, 2-pyridinyl-methyl, 3- pyridinyhnethyl, 4-pyridinykαethyl, l-methyl-4-piperidinyl, 4-piperidinyl, (6-methyl- pyridin-2-yl)methyl, (2-ethyl-4-methyl-lH-imidazol-5-yl)methyl, tetrahydrofuran-2- yl, tetrahydrofuran-3-yl, tetrahydroruran-3-yhnethyl, 1 -ethyl- lH-pyrazol-4-yI, 1,3- dimethyl-lH-pyrazol-5-yl, (3-methylpyridin-4-yl)methyl, l,3-oxazol-2-yknethyl, 1,3- oxazol-5-ylmethyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H-pyran-4- ylmethyl, 2-phenylethyl, 2-methoxybenzyl, 3,3,3-trifluoropropyl, 2,2-difluoroethyl, 2- hydroxycyclopentyl, (l-ethyI-3-methyl-lH-pyrazol-5-yl)methyl, 2,1,3-benzoxadiazol- 5-yhnethyl, 3-thienylmethyl, 2-trifluoromethyl-benzyl, 3-methylbutyl, cyclohex-3-en- 1-yknethyl, 2-fluoro-6-methoxybenzyl, 2-phenyl-propyl, 2-ethyl-butyl, cyclobutylcarbonyl, 2,2-difluoropropanoyl, cyclopentylcarbonyl, tetrahydro-2H- pyran-4-ylcarbonyl, cyclopropylcarbonyl, propylcarbonyl, N-ethylaminocarbonyl, N- isopropylaminocarbonyl, cyclopropylsulfonyl, and ethylsulfonyl.

3. A compound as claimed in claim 1, wherein R¹ is selected from methyl, ethyl and cyclopropyl;

R² is selected from -H, methyl, 1-furylsulfonyl, methylsulfonyl and ethylsulfonyl; and

R³ is selected from ethyl, isopropyl, propyl, 2-methy-propyl, 1 -butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 1-iminoethyl, 3,4,5,6-tetrahydropyrdin-2-yl, 3,4-dihydro- 2H-pyrrol-5-yl, tetrahydroruran-3-ylmethyl, tetrahydrofuran-2-yl, tetrahydrofuran-3- yl, l-methyl-4-piperidinyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H-pyran-4- ylmethyl, 3,3,3-trifluoropropyl, 2,2-difluoroethyl, 2-hydroxycyclopentyl, 3- methylbutyl, cycIohex-3-en-l-yhnethyl, and 2-ethyl-butyl.

4. A compound selected from

N-Cyclopropyl-l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH- pyrido[4,3-Z)]indol-8-yl]carbonyl}piperidine-3-carboxamide; N-Cyclopropyl-l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH- pyrido[4,3-Z?]indol-8-yl]carbonyl}pyrrolidine-3-carboxamide;

N-Cyclopropyl-2-(l-{[5-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-terrahydro-lH- pyrido[4,3-Z)]indol-8-yl]carbonyl}azetidin-3-yl)acetamide;

Ν-C^clopropyl-l-{[5-me1tyl-2-(tetrahydro-2Η-pyran-4-yl)-2,3₃4,5-te1xahydro-lΗ- pyrido[4,3-b]indol-8-yl]carbonyl}azetidine-3-carboxamide;

(3R)4-{[2-Cyclopentyl-5-(2-furylsulfonyl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indol-

8-yl]carbonyl} -N-cyclopropylpiperidine-3 -carboxamide;

(S^-l-IP-Cyclopentyl-S-Cethylsulfony^^^^^-tetrahydro-lH-pyridoμ^-^indol-δ- yl]carbonyl}-N-cyclopropylpiperidine-3-carboxamide; (3R)-l-{[2-Cyclopentyl-5-(methylsulfonyl)-2,3,4,5-tetrahydro-lH-pyrido[4,3-έ]indol-

8-yI]carbonyl}-N-cyclopropylpiperidine-3-carboxamide;

(35)-l-{[2-(^clopen1yl-5-(e%lsιdfonyl)-2,3,4,54elxahydro-lH-pyrido[4,3-i]indoi-8- yl]carbonyl} -N-cyclopropylpiperidine-S-carboxamide; (3^-l-{[5-(E%lsulfonyl)-2-(te1τahydro-2H-pyra-i-4-yl)-2,3Λ5-tetrahydro-lH- pyrido[4,3-o]indol-8-yl]carbonyl}-N-methylpiperidine-3-carboxamide; (35)-N-E%l-l-{[5-(ethylsιdfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro- lH-pyrido[4,3-έ]indol-8-yl]carbonyl}piperidine-3-carboxamide; (3S)-l-{[5-(Ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-lH- pyrido[4,3-&]indol-8-yl]carbonyl}-N-isopropylpiperidine-3-carboxamide; (3S)-N-Cyclopropyl-l-{[5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5- tetrahydro-lH-pyrido[4,3-Z)]indol-8-yl]carbonyl}piperidine-3-carboxamide; and pharmaceutically acceptable salts thereof.

5. A compound according to any one of claims 1-4 for use as a medicament.

6. The use of a compound according to any one of claims 1-4 in the manufacture of a medicament for the therapy of pain.

7. The use of a compound according to any one of claims 1-4 in the manufacture of a medicament for the treatment of anxiety disorders.

8. The use of a compound according to any one of claims 1-4 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson' s disease,

Ηuntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders.

9. A pharmaceutical composition comprising a compound according to any one of claims 1-4 and a pharmaceutically acceptable carrier.

10. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-4.